Current and emerging treatment options for migraine and other primary headache disorders

References

• Rasmussen BK. Epidemiology of headache. Cephalalgia 15,45–68 (1995).
   PubMed Web of Science ®Google Scholar
• Hu XH, Markson LE, Lipton RB eta]. Burden of migraine in the United States: disability and economic costs. Arch Intern. Med. 159,813-818 (1999).
   Google Scholar
• Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 8\(Suppl. 7), 1–93 (1988).
   Google Scholar
• Schwartz BS, Stewart WF, Simon D et al Epidemiology of tension-type headache. JA/V/A 279,381–383 (1998).
   Google Scholar
• Rasmussen B, Jensen R, Schroll M eta! Epidemiology of headache in a general population: a prevalence study. J. Clin. Epidemiol 44,1147–1157 (1991).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Hamelsky SW, Stewart WF. Epidemiology and impact of headache. Am. Acad. Neural. 200 Syn. 7AC.001-1 — 7AC.001–30 (2001).
   Google Scholar
• Rasmussen BK, Jensen R, Olesen J. Impact of headache on sickness absence and utilisation of medical services: a Danish population study. J. Epidemiol. Corn. Health. 46,443-446 (1992).
   Google Scholar
• Schwart BS, Stewart WF, Lipton RB. Lost workdays and decreased work effectiveness associated with headache in the workplace. Occup. Environ. Med. 39,320–327 (1997).
   Google Scholar
• Lavados P, Tenhamm E. Epidemiology of tension-type headache in Santiago, Chile: a prevalence study. Cephalalgia 18,552–558 (1998).
   PubMed Web of Science ®Google Scholar
• Vandenheede M, Schoenen J. Central mechanisms in tension-type headaches. Cum Pain Headache Rep. 6(5), 392–400 (2002).
   Google Scholar
• •Current review of the pathophysiology of tension-type headache.
   Google Scholar
• Bendtsen L. Central sensitization in tension-type headache — possible pathophysiological mechanisms. Cephalalgia 20,486–508 (2000).
   PubMed Web of Science ®Google Scholar
• Jensen R. Peripheral and central mechanisms in tension-type headache: an update. Cephalalgia23\(Suppl. 1), 49–52 (2003).
   Google Scholar
• Jensen R. Tension-type headache. Cur 7i-eat. Options Neural. 3(2), 169–180 (2001).
   Google Scholar
• Mathew N, Schoenen J. Acute Pharmacotherapy of tension-type headache. In The Headaches. Second Edition. Olesen J, Tfelt-Hansen, Welch MA (Eds). Lippincott, Williams and Wilkins, PA, USA, 661–666 (2000).
   Google Scholar
• Sheftell FD. Role and impact of over-the- counter medications in the management of headache. Neurologic Clinics. 15 (1), 187–200 (1997).
   Google Scholar
• •Thorough review of the role of over-the-counter medications in primary headache disorders.
   Google Scholar
• Stillman MJ. Pharmacotherapy of tension- type headache. CI.117: Pain Headache Rep. 6(5), 408–413 (2002).
   Google Scholar
• Redillas C, Solomon S. Prophylactic pharmacological treatment of chronic daily headache. Headache 40,83–102 (2000).
   PubMed Web of Science ®Google Scholar
• Holroyd KA. Behavioral and psychologic aspects of the pathophysiology and management of tension-type headache. Cum Pain Ikadache Rep. 6(5), 401–407 (2002).
   Google Scholar
• •Highlights the role of nonpharrnacologic modalities in the management of tension-type headache.
   Google Scholar
• Vernon H, McDermain CS, Hagino C eta! Systematic review of randomized clinical trials of complimentary/alternative therapies in the treatment of tension-type and cervicogenic headache. Complement Ther. Med 7,142–155 (1999).
   PubMedGoogle Scholar
• Edmeads J, Findlay H, Tugwell P et al Impact of migraine and tension-type headache on life-style, consulting behaviour and medication use: a Canadian population survey. Can. J. Nemo'. Li. 20, 131–137 (1993).
   Google Scholar
• Limmroth V, Katsarava Z, Diener HC. Acetylsalicylic acid in the treatment of headache. Cephalagia 19 (6), 545–551 (1999).
   PubMed Web of Science ®Google Scholar
• Hersh EV, Moore PA, Ross GL. Over-the- counter analgesics and antipyretics: a critical assessment. Clin. Ther 22(5), 500–548 (2000).
   Google Scholar
• Langemark M, Olesen J. Effervescent ASA versus solid ASA in the treatment of TTH: a double-blind, placebo-controlled study. Headache 27,90–95 (1987).
   PubMed Web of Science ®Google Scholar
• Peters BH, Fraim CJ, Masel BE. Comparison of 650 mg aspirin and 1000 mg acetaminophen with each other and with placebo in moderately severe headache. Am. J. Med. 74,36-42 (1983).
   Google Scholar
• Steiner TJ, Lange R, Voelker M. Aspirin in episodic tension-type headache: placebo-controlled dose-ranging comparison with paracetamol. Cephalalgia 23,59–66 (2003).
   PubMed Web of Science ®Google Scholar
• Schachtel BP, Furey SA, Thoden WR. Nonprescription ibuprofen and acetaminophen in the treatment of tension-type headache. J. Clin. Pharmacol. 36(12), 1120–1125 (1996).
   Google Scholar
• Prior MJ, Cooper KM, May LG eta! Efficacy and safety of acetaminophen and naproxen in the treatment of tension-type headache. A randomized, double-blind, placebo-controlled trial. Cephalalgia 22(9), 740–748 (2002).
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Lange R. Ketoprofen (25 mg) in the symptomatic treatment of episodic tension-type headache: double-blind placebo-controlled comparison with acetaminophen (1000 mg). Cephalalgia 18,38–43 (1998).
   PubMed Web of Science ®Google Scholar
• Lange R, Lentz R. Comparison of ketoprofen, ibuprofen and naproxen sodium in the treatment of tension-type headache. Drugs Explt. Clin. Res. 3,89–96 (1995).
   Google Scholar
• Schachtel BP, Furey SA, Thoden WR. Nonprescription ibuprofen and acetaminophen in the treatment of tension-type headache. J. Clin. Pharmacol 1120–1125 (1996).
   Google Scholar
• Dahlof CGH, Jacobs LD. Ketoprofen, paracetamol and placebo in the treatment of episodic tension-type headache. Cephalalgia 16,117–123 (1996)
   PubMed Web of Science ®Google Scholar
• Packman B, Packman E, Doyle G eta]. Solubilized ibuprofen: evaluation of onset, relief and safety of a novel formulation in the treatment of episodic tension-type headache. Headache 40 (7), 562–567 (2000).
   Web of Science ®Google Scholar
• Wright JM. The double-edged sword of COX-2 selective NSAIDs. CM4J167 (10), 1131-1137(2002).
   Google Scholar
• Diamond S, Freitag PH. The use of ibuprofen plus caffeine to treat tension-type headache. Cur Pain Headache Rep. 5(5), 472–478 (2001).
   Google Scholar
• Migliardi JR, Armellino JJ, Friedman M eta]. Caffeine as an analgesic adjuvant in tension-type headache. Clin. Pharmacol Ther 56(5), 576–586 (1994).
   Google Scholar
• Ward N, Whitney C, Avery D eta]. The analgesic effects of caffeine in headache. Pain 44,151–155 (1991).
   Google Scholar
• Silberstein SD, McCrory DC. Butalbital in the treatment of headache: history, pharmacology and efficacy. Headache 41, 953–967 (2001).
   PubMed Web of Science ®Google Scholar
• •Excellent overview of the role of butalbital in headache treatment.
   Google Scholar
• Solomon S. Butalbital-containing agents: should they be banned? No. CU17: Pain Headache Rep. 6(2), 147–150 (2002).
   Google Scholar
• Young WB, Slow HC. Should butalbital- containing analgesics be banned? Yes. Curl: Pain Headache Rep. 6(2), 151–155 (2002).
   Google Scholar
• Lipton RB, Stewart WF, Cady R et al 2000 Wolfe Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache 40(10), 783–791 (2000).
   Google Scholar
• Leston JA. Migraine and tension-type headache are not separate disordes. Cephalalgia 16,217–220 (1996).
   PubMed Web of Science ®Google Scholar
• Rasmussen BK. Migraine and tension-type headache are separate disorders. Cephalalgia 16,220–223 (1996).
   PubMed Web of Science ®Google Scholar
• Rothrock JE What& apos;s in a name? Tension- type headache versus migraine. Curl: Pain Headache Rep. 5(5), 463–466 (2001).
   Google Scholar
• Schattner P, Randerson D. Tiger Balm as a treatment of tension headache. A clinical trial in general practice. Aust. Fain. Physician 25(2), 216–220 (1996).
   Google Scholar
• Gobel H, Fresenius J, Heinze A et al Effectiveness of Oleum menthae piperitae and paracetamol in therapy of headache of the tension type. Nervenarzt. 67(8), 672–681(1996).
   Google Scholar
• Silberstein SD, Lipton RB. Chronic daily headache. Curl: Opin. Neuml 13,277–288 (2000).
   Web of Science ®Google Scholar
• Holroyd KA, Odonnell FJ, Stensland M eta]. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy and their combination. PIN/A 285(7), 2208–2215 (2001).
   Google Scholar
• •Important study demonstrating the synergistic effect of nonpharrnacologic and pharrnacologic modalities.
   Google Scholar
• Langemark M, Loldrup D, Bech P eta! Clomipramine and mianserin in the treatment of chronic tension headache: a double-blind, controlled study. Headache 30,118–121 (1990).
   PubMed Web of Science ®Google Scholar
• Manna V, Bolino F, DiCicco L. Chronic tension-type headache: a placebo-controlled double-blind crossover study. Headache 34,44–49 (1994).
   PubMed Web of Science ®Google Scholar
• Rollnik JD, Tanneberger 0, Schubert M eta! Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study. Headache 40,300–305 (2000).
   PubMed Web of Science ®Google Scholar
• Evers S, Rahmann A, vollmer-Haase J eta! Treatment of headache with botulinum toxin A — a review according to evidence based medicine criteria. Cephalalgia 22(9), 699–710 (2002).
   PubMed Web of Science ®Google Scholar
• Ondo WG, Vuong KD, Derman HS. Botulinum toxin A (BOTOX) for chronic daily headache: a randomized placebo-controlled, parallel design study. American Headache Society 44th Annual Scientific Meeting. Seattle, WA, USA, June 21–24 (2002).
   Google Scholar
• Saper Jr, Laker AE, Cantrell DT et al Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache 42 (6), 470–482 (2002).
   PubMed Web of Science ®Google Scholar
• Ashina M. Nitric oxide synthase inhibitors for the treatment of chronic tension-type headache. Expert Opin. Pharmacother. 3(4), 395–399 (2002).
   Google Scholar
• Hamelsky SW, Stewart WF, Lipton RB. Epidemiology of migraine. Gun: Pain Headache Rep. 5(2). 189–194 (2001). 5657) Goadsby PJ, Lipton RB, Ferrari MD. Migraine — current understanding and treatment. N Engl. J. Med. 346(4), 157–170 (2002).
   Google Scholar
• ••State of the art review of migrainepathophysiology and treatment.
   Google Scholar
• Scher A, Stewart W, Lipton RB. Migraine and headache: a meta-analytic approach. In: Epidemiology of Pain. Crombie I (Ed.). IASP Press, Seattle, WA, USA, 159–170 (1999).
   Google Scholar
• Lipton R, Hamelsky S, Kolodner K eta! Migraine, quality of life and depression: a population-based case-control study. Neurology55, 629–635 (2000).
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Lipton RB, Liberman JN et al Work and family impact of migraine: a population-based case-control study. Neurology 52 (Suppl. 2), A470—A471 (1999).
   Google Scholar
• Lipton RB, Stewart WF, Diamond S eta! Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41(7), 646–657 (2001).
   PubMed Web of Science ®Google Scholar
• Aurora SK. Pathophysiology of migraine headache. Gun: Pain Headache Rep. 5 (2), 179–182 (2001).
   Google Scholar
• •Current review of migraine pathophysiology.
   Google Scholar
• May A. Headache: lessons learned from functional imaging. BE Med. Bull. 65, 223–234 (2003).
   PubMed Web of Science ®Google Scholar
• Hadjikhani N, Sancez Del Rio M, Wu 0 eta! Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc. Natl Acad. Li. USA 98(8), 4687–4692 (2001).
   Google Scholar
• Bolay H, Reuter U, Dunn AK eta! Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat. Med. 8(2), 136–142 (2002).
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Neumlogy55,754-762 (2000). US Headache Consortium guidelines for the pharrnacologic treatment of migraine.
   Google Scholar
• Lipton RB, Stewart WF, Stone AM eta! Stratified care versus step care strategies for migraine. The Disability in Strategies of Care (DISC) Study: a randomized trial. JAIVIA 284(20), 2599–2605 (2000).
   PubMed Web of Science ®Google Scholar
• •Important study illustrating the benefits of the stratified care treatment strategy
   Google Scholar
• Lipton RB, Stewart WF, Sawyer J. Stratified care is a more effective migraine treatment strategy than stepped care: results of a randomized clinical trial. Neurology 54\(Suppl. 3), A14 (2000).
   Google Scholar
• Cady R, Dodick DW. Migraine headache: a new look at diagnosis, treatment and efficacy evaluation. Mayo Clinic Proc.77 (3), 255–261 (2002).
   PubMed Web of Science ®Google Scholar
• Schoenen J. When should triptans be taken during a migraine attack? CNS Drugs 15(8), 583–587 (2001).
   Google Scholar
• Burstein R, Cutrer ME, Yarnitsky D. The development of cutaneous allodynia during a migraine attack: clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 123,1703–1709 (2001).
   Web of Science ®Google Scholar
• Burstein R, Collins B, Bajwa Z eta! Triptan therapy can abort migraine attacks if given before the establishment or in the absence of cutaneous allodynia and central sensitization: clinical and preclinical evidence. Headache 42,390 (2002).
   Google Scholar
• Winner P, Mannix L, McNeal S eta! Treatment of migraine at the first sign of pain: prospective, double-blind, placebo-controlled, multicenter studies of sumatriptan 50 mg and 100 mg versus placebo. Neurology 58 (Suppl. 3), A415 (2002).
   Google Scholar
• KLapper JA, Charlesworth B, Jergenson AP eta! Treatment of mild migraine with oral zolmitriptan 2.5 mg prevents progression to more severe migraine and reduces the impact on normal activities in patients with significant migraine-related disability. Neumlogy58\(Suppl. 3), A291—A292 (2002).
   Google Scholar
• Burstein R, Collins B, Bajwa Z eta! Triptan therapy can abort migraine attacks if given before the establishment or in the absence of cutaneous allodynia and central sensitization: clinical and preclinical evidence. Headache 42,390 (2002).
   Google Scholar
• Martin VT, Behbehani MM. Toward a rational understanding of migraine trigger factors. Med. Clin. North Am. 85(4), 911–941 (2001).
   Google Scholar
• Limmroth V, Przywara S. Analgesics. In: Drug Treatment of Mgraine and Other Headaches. Diener HC (Ed.). Monogr Gun. Neurosci. Basel, Switzerland. 17,30-43 (2000).
   Google Scholar
• Boureau F, Joubert JM, Lasserre V et al. Double-blind comparison of an acetaminophen 400 mg-codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia 14(2), 156–161 (1994).
   Google Scholar
• MacGregor EA, Dowson A, Davies PT Mouth-dispersible aspirin in the treatment of migraine: a placebo-controlled study. Headache 42,249–255 (2002).
   PubMed Web of Science ®Google Scholar
• Lange R, Schwarz JA, Hohn M. Acetysalicylic acid effervescent 1000mg (Aspirin) in acute migraine attacks; a mutlicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgra 20,663–667 (2000).
   Google Scholar
• Tfelt-Hansen P, Henry P, Mulder LJ et al The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 346,923–926.
   Google Scholar
• Kaube H, Hoskin KL, Goadsby PJ. Acetylsalicylic acid inhibits cerebral central cortical vasodilation caused by superior sagittal sinus stimulation in the cast. Eur Neural. 1,141–146 (1994).
   Google Scholar
• Larsen BH, Christiansen LV, Andersen B et al Randomized double-blind comparison of tolfenamic acid and paracetamol in migraine. Acta Neural. Scand. 81,464–467 (1990).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Baggish JS, Stewart WF eta! Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern. Med. 160(22), 3486–3492 (2000).
   Web of Science ®Google Scholar
• Codispoti JR, Prior MJ, Fu M eta]. Efficacy of nonprescription doses of ibuprofen for treating migraine headache. Headache 41 (7), 665–679 (2001).
   PubMed Web of Science ®Google Scholar
• Kellstein DE, Lipton RB, Geetha R eta].Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study. Cephalalgra 20(4), 233–243 (2000).
   PubMed Web of Science ®Google Scholar
• Shrestha M, Singh R, Moreden J eta! Ketorolac vs. chlorpromazine in the treatment of acute migraine without aura. A prospective, randomized, double-blind trial. Arch Intern. Med. 156 (15), 1725–1728 (1996).
   Google Scholar
• Rasmussen MK, Binzer M. Nonsteroidal anti-inflammatory drugs in the treatment of migraine. Curr. Med. Res. Opin. 17\(Suppl. 1), 26–29 (2001).
   Google Scholar
• Did M, Massiou H, Weber M eta! Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. Neurology58(11), 1660–1665 (2002).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF, Ryan RE Jr eta]. Efficacy and safety of acetaminophen, aspirin and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials. Arch Neural. 55(2), 210–217 (1998).
   PubMedGoogle Scholar
• Freitag FG, Cady R, DiSerio F et al Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine. Headache 41(4), 391–398 (2001).
   PubMed Web of Science ®Google Scholar
• Goldstein J, Gawel MJ, Winner P eta! Comparison of Butorphanol nasal spray with Fiorinal with Codeine in the treatment of migraine. Headache 38, 516–522 (1998).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, McCrory DS. Opioids. Cephalalgra 20,854–864 (2000).
   PubMed Web of Science ®Google Scholar
• ••Excellent overview of the role of opioids inthe management of primary headache disorders.
   Google Scholar
• Boureau F, Joubert JM, Lasserre V et al Double-blind comparison of an acetaminophen 400mg-codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine. Cephalalgia 14(2), 156–161 (1994).
   Google Scholar
• Ziegler DK. Opioids in headache treatment. Is there a role? Neural. Clin. 15(1), 199–207 (1997).
   Google Scholar
• Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology and efficacy. Headache 43, 144–166(2003).
   PubMed Web of Science ®Google Scholar
• Matthew NT Dosing and administration of ergotamine and dihydroergotamine. Headache 37\(Suppl. 1), S26—S32 (1997).
   Google Scholar
• Lipton RB. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache 37 (Suppl. 1), S33—S41 (1997).
   Google Scholar
• Bigal ME, Tepper SJ. Ergotamine anddigydroergotamine: a review. Curr. Pain Headache Rep. 7(1), 55–62 (2003).
   PubMedGoogle Scholar
• •Current review summarizing the role of ergotamine and dihydroergotamine (DHE) in migraine therapy.
   Google Scholar
• Cady RK, Wendt JK, Kirchner JF, et al Treatment of acute migraine with sc. sumatriptan. JAMA 265,2831–2835 (1991).
   PubMed Web of Science ®Google Scholar
• The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J. Med. 325,316–321 (1991).
   PubMed Web of Science ®Google Scholar
• Dahlof C. Sumatriptan nasal spray in the acute treatment of migraine. A review of clinical studies. Cephalalgia 19,769–778 (1999).
   PubMed Web of Science ®Google Scholar
• Pfaffenrath V, Cunin G, Sjonell G eta! Efficacy and safety of sumatriptan tablets in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan. Headache 38,184–190 (1998).
   PubMed Web of Science ®Google Scholar
• Sargent J, Kirchner JR, Davis R eta! Oral sumatriptan is effective and well-tolerated for the acute treatment of migraine: Results of a multicenter study. Neurology45\(Suppl. 7), S10—S14 (1995).
   Google Scholar
• Cutler N, Mushet GR, Davis R eta]. Oral sumatriptan for the acute treatment of migraine: Evaluation of three dosage strengths. Neurology45\(Suppl. 7), S5—S9 (1995).
   Google Scholar
• Adelman JU, Sharfman M., Johnson R. eta! Impact of oral sumatriptan on workplace productivity, health-related quality of life, healthcare use and patients satisfaction with medication in nurses with migraine. Am.j Man. Care 2,1407–1416 (1996).
   Google Scholar
• Maassen VanDenBrink A, Reekers M, Bax WA eta]. Circulation 98(1), 25–30 (1998).
   PubMedGoogle Scholar
• Nappi G, Sandrini G, Sances G eta! Tolerability of the triptans: clinical implications. Drug- Safety26(2), 93–107 (2003).
   PubMed Web of Science ®Google Scholar
• Welch KMA, Mathew NT, Stone P eta! Tolerability of sumatriptan: clinical trials and postmarketing experience. Cephalalgra 8,687–695 (2000).
   Google Scholar
• Evans RVV, Martin V. Asessing cardiac risk prior to the use of triptans. Headache 40, 599–602 (2000).
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Dr Vries P, Saxena PR. Triptans in migraine, a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60(6), 1259–1287 (2000). in Dahl& CGH, Dodick DW, Dowson AJ, Pascual J. How does Almotriptan compare to other triptans? A review of data from placebo-controlled clinical trials. Headache 42(2), 99–113 (2002).
   Google Scholar
• Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT113/ ID agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358, 1668–1675 (2001). 22, 491–512 (2002).
   PubMed Web of Science ®Google Scholar
• •Excellent overview of the currently available options for prophylactic treatment of migraine.
   Google Scholar
• Krymchantowski AV, Bigal ME, Moreira PP et al New and emerging prophylactic agents for migraine. CNS Drugs 16(9)
   Google Scholar
• •Detailed summary of the current and emerging prophylactic agents for migraine.
   Google Scholar
• Limmroth V, Mummel P Migraine
   Google Scholar
• Etminan M, Levine M, Tomlinson G eta]. Efficacy of angiotensin II receptor antagonists in preventing headache: a
   Google Scholar
• Mathew NT, Silberstein SD. Anticonvulsants in migraine prophylaxis. In: Drug Treatment of !Ukraine and Other Headaches. Diener HC (Ed.). Monogr: Gun. Neurosci. Basel, Switzerland 17,288–298 (2000).
   Google Scholar
• Wheeler SD. Antiepileptic drug therapy in migraine headache. CI.117: Treat Op. Neurology4,383–394 (2002).
   Google Scholar
• Cutrer FM. Antiepileptic drugs: how they work in headache. Headache 41 (Suppl. 1), S3—S10 (2001).
   Google Scholar
• Mathew NT Antiepileptic drugs in migraine prevention. Headache 41 (Suppl. 1), S18—S24 (2001).
   Google Scholar
• Freitag FG, Collins SD, Carlson BA eta]. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology58,1652–1659 (2002).
   Google Scholar
• Mathew NT, Rapoport A, Saper J et al Efficacy of gabapentin in migraine prophylaxis. Headache 41 (2), 119–128 (2001).
   PubMed Web of Science ®Google Scholar
• Schoonman GG, Wiendels NJ, Ferrari MD. Gabapentin in migraine prophylaxis: is it effective and well-tolerated? Headache 42(3), 235 (2002).
   Google Scholar
• Storey JR, Calder CS, Hart De eta! Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 41,968–975 (2001).
   PubMed Web of Science ®Google Scholar
• Mathew NT, Schmitt J, Jacobs D eta]. Topiramate in migraine prevention (MIGR-001): effect on migraine frequency. Neuomlogy 60(5) (Supp. 1), A336.
   Google Scholar
• Toda N, Tfelt-Hansen P Calcium channel antagonist in migraine prophylaxis. In: The Headaches. Second Edition. Olesen J, Tfelt-Hansen, Welch MA (Eds). Lippincott, Williams and Wilkins, PA, USA, 477–482 (2000).
   Google Scholar
• Diener HC. Flunarizine for migraine prophylaxis. In: Drug Treatment of !Ukraine and Other Headaches. Diener HC (Ed.). Monogr: Gun. Neurosci. Basel, Switzerland 17,269–278 (2000).
   Google Scholar
• Silberstein SD. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin. Pharamcother. 2(10), 1649–1654 (2001).
   Google Scholar
• Silberstein S, Mathew N, Saper J eta! Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 40 (6), 445–450 (2000) .Barrientol S, Chana P Efficacy and safety of botulinum toxin type A (BOTOX) in the prophylactic treatment of migraine. American Headache Society 44th Annual Scientific Meeting. Seattle, WA, USA. June 21–23 (2002).
   Google Scholar
• Eross EG, Dodick DW. The effects of botulinum toxin type A on disability in episodic and chronic migraine. American Headache Society 44th Annual Scientific Meeting. Seattle, WA, USA, June 21–23, (2002).
   Google Scholar
• Bluring JE, Peto R, Hennekens CH. Low-dose aspirin for migraine prophylaxis. JAIVIA 264(13), 1711–13 (1990).
   PubMed Web of Science ®Google Scholar
• Peto R, Gray R, Collins R eta]. Randomized trial of prophylactic daily aspiring in British male doctors. BE Med. j 296,313–316 (1988).
   PubMed Web of Science ®Google Scholar
• Bensenor IM, Cook NR, Lee IM eta]. Low-dose aspirin for migraine prophylaxis in women. Cephalalgla 21(3), 175–183 (2001).
   PubMed Web of Science ®Google Scholar
• Diener HC, Hartung E, Chrubasik J et al A comparative study of oral acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. A randomized, controlled, double-blind, parallel group Phase III study. Cephalalgia 21(2), 120–128 (2001).
   PubMed Web of Science ®Google Scholar
• Schrader H, Stovener LJ, Helde G eta]. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo-controlled, crossover study. BE Med j 322(7277), 19–22 (2001).
   PubMedGoogle Scholar
• Tronvik E, Stovner LJ, Helde G eta]. Prophylactic treatment of migraine with an angiotensin II receptor blocker — a randomized controlled trial. JAMA 289, 65–69 (2003).
   Google Scholar
• Pittler MET, Vogler BK, Ernst E. Feverfew for preventing migraine. Cochrane Database Sys. Rev 3, CD002286 (2000).
   Google Scholar
• Diener HC, Fischer M etal. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis — a double-blind, multicenter, randomized, placebo-controlled dose-response study. Cephalalgla 22(7), 523–532 (2002).
   PubMed Web of Science ®Google Scholar
• Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis — a randomized controlled trial. Neurology50, 466–470 (1998).
   Google Scholar
• Pfaffenrath V, wessely P, Meyer C eta]. Magnesium in the prophylaxis of migraine — a double-blind, placebo-controlled study. Cephalalgia 16,436–440 (1996).
   Google Scholar
• Peikert A, Wilimzig C, Kohne-Wolland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multicenter, placebo-controlled and double-blind randomized study. Cephalalgia 16,257–263 (1996).
   PubMed Web of Science ®Google Scholar
• Mauskop A, Altura BM. Role of magnesium in the pathogenesis and treatment of migraine. Gun. Neurosci. 5(1), 24–27 (1998).
   Web of Science ®Google Scholar
• Rozen TD, Oshinsky ML, Gebeline CA et al Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 22, 137–141 (2002).
   PubMed Web of Science ®Google Scholar
• Grossmann M, Schmidramsl H. An extract of petasites hybridus is effective in the prophylaxis of migraine. Int. j Gun. Pharmacol Ther. 38(9), 430–435 (2000).
   Google Scholar
• Dodick DW, Tozen TD, Goadsby PJ eta]. Cluster headache. Cephalalgla 20,787–803 (2000).
   PubMed Web of Science ®Google Scholar
• •Detailed overview of the epidemiology, pathophysiology and treatment of cluster headache.
   Google Scholar
• Ekbom K, Hardebo JE. Cluster headache: aetiology, diagnosis and management. Drugs62(1), 61–69 (2002).
   PubMed Web of Science ®Google Scholar
• Dodick DW, Capobianco DJ. Treatment and management of cluster headache. Cur. Pain Headache Rep. 5(1), 83–91 (2001).
   PubMedGoogle Scholar
• Aurora SK. Etiology and pathogenesis of cluster headache. Curl: Pain Headache Rep. 6(1), 71–75 (2002).
   Google Scholar
• Pringsheim T Cluster headache: evidence for a disorder of circadian rhythm and hypothalamic function. Can. j Nemo'. Sc]. 29(1), 33–40 (2002).
   Google Scholar
• Russel MB. Genetic epidemiology of migraine and cluster headache. Cephalalgla 17,683–701 (1997).
   PubMed Web of Science ®Google Scholar
• Leone M, Bussone G. A review of hormonal findings in cluster headache. Evidence for hypothalamic involvement. Cephalalgia 13,309–317 (1993).
   PubMed Web of Science ®Google Scholar
• May A, Bahra A, Buchel C eta]. Hypothalamic activation in cluster headache attacks. Lancet 352,275–278 (1998).
   Google Scholar
• May A, Ashbumer J, Buchel C eta]. Correlation between structural and functional changes in brain in an idiopathic headache syndrome. Nat. Med. 5,836–838 (1999).
   Google Scholar
• May A, Bahra A, Buchel C eta]. PET and MRA findings in cluster headache and MRA in experimental pain. Neurology 55, 1328–1335 (2000).
   Google Scholar
• Rozen TD. New treatments in cluster headache. CUE Afrual. Neurosci. Rep. 2, 114–121 (2002).
   PubMedGoogle Scholar
• Ekbom K. Treatment of acute cluster headache with sumatriptan. N Engl. Med. 325,322–326 (1991).
   PubMed Web of Science ®Google Scholar
• Gobel H, Linder V, Heinze A eta]. Acute therapy for cluster headache with sumatriptan: findings of a one-year long-term study. Neurology51,908–911 (1998).
   PubMed Web of Science ®Google Scholar
• Van Vliet JA, Bahra A, Martin V et al. Intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study. Neurology 60,630–633 (2003).
   PubMed Web of Science ®Google Scholar
• Bahra A, Gawel MJ, Hardebo JE eta]. Oral zolmitriptan is effective in the acute treatment of cluster. Neurology 54, 1832–1839 (2000).
   Google Scholar
• Fogan L. Treatment of cluster headache. A double-blind comparison of oxygen air inhalation. Arch Neural 42,362–363 (1985).
   Google Scholar
• Kudrow L. Response of cluster headache attacks to oxygen inhalation. Headache 21, 1–4 (1981).
   PubMed Web of Science ®Google Scholar
• Robbins L. Intranasal lidocaine for cluster headache. Headache 35,83–84 (1995).
   PubMed Web of Science ®Google Scholar
• Andersson PG, Jespersen LT Dihydroergotamine naal spray in the treatment of attacks of cluster headache. Cephalalgia 6,51–54 (1986).
   PubMed Web of Science ®Google Scholar
• Rozen TD. Olanzapine as an abortive agent for cluster headache. Headache 41, 813–816 (2001).
   PubMed Web of Science ®Google Scholar
• Anthony M, Daher BN. Mechanisms of action of steroids in cluster headache. In: New Advances in Headache Resealrh 2. Rose PC (Ed.). Smith Gordon, London, UK, 271–274 (1992). 164 Mather PJ, Silberstein SD, Schulman EA et al The treatment of cluster headachewith repetitive intravenous dihydroergotamine. Headache 31,525–532 (1991).
   Google Scholar
• Mulder LJ, Spierings EL. Naratriptan in the preventive treatment of cluster headache. Cephalalgia 22,815–817 (2002).
   PubMed Web of Science ®Google Scholar
• Leone M, D'Amico D, Attanasio A eta]. Verapmail is an effective prophylactic for cluster headache: results of a double-blind multicenter study versus placebo. In: Cluster Headache & Related Conditions. Olesen J, Goadsby PJ (Eds). Oxford University Press, Oxford, UK, 296–299 (1999).
   Google Scholar
• Stiener TJ, Hering R, couturier ECM et al Double-blind placebo-controlled trial of lithium in episodic cluster headache. Cephalalgia 17,673–675 (1997).
   PubMed Web of Science ®Google Scholar
• Bussone G, Leone M, Peccarisi C. Double-blind comparison of lithium and verapamil in cluster headache prophylaxis. Headache 30,411–417 (1990).
   Google Scholar
• Curran DA, Hinterburger H, Lance JW Methysergide. Res. Clin. Stud. Head. 1, 74–122 (1967).
   Google Scholar
• Rozen TD. Antiepileptic drugs in the management of cluster headache and trigeminal neuralgia. Headache 41 (Supp. 1), S24—S32 (2001).
   Google Scholar
• El Amrani M, Masssiou H, Bousser MG. A negative trial of sodium valproate in cluster headache: methodological issues. Cephalalgia 22,205–208 (2002).
   PubMed Web of Science ®Google Scholar
• Lainez MJ, Pascual K, Santonja JM eta! Topiramate in the prophylactic treatment of cluster headache. Cephalalgia 21,500 (2001).
   Google Scholar
• Forderreuther S, Mayer M, Straube A. Treatment of cluster headache with topiramate: effects and side effects in five patients. Cephalalgia 22 (3), 186–189 (2002).
   PubMed Web of Science ®Google Scholar
• Wheeler SD, Carrazana EJ. Topiramate-treated cluster headache. Neurology 53(1), 234–236(1999)
   PubMed Web of Science ®Google Scholar
• McGeeney BE. Topiramate in the treatment of cluster headache. G117: Pain Headache Rep. 7(20), 135–138 (2003).
   Google Scholar
• Leandri M, Luzzani M, Cruccu G eta]. Drug-resistant cluster headache responding to gabapentin: a pilot study. Cephalalgia 21, 744–746 (2001).
   PubMed Web of Science ®Google Scholar
• Leone M, Damico D, Moschiano F eta]. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia 16,494–496 (1996).
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Magnoux E, Dobson CF eta! Melatonin as adjunctive therapy in the prophylaxis of cluster headache: a pilot study. Headache 42(8), 787–792 (2002).
   PubMed Web of Science ®Google Scholar
• Marks DR, Rapoport A, Padla D etal. A double-blind placebo-controlled trial of intranasal capsaicin for cluster headache. Cephalalgia 13(2), 114–116 (1993).
   PubMed Web of Science ®Google Scholar
• Saper JR, KLapper J, Matthew NT et al Intranasal civamide for the treatment of episodic cluster headaches. Arch Neural 59(6), 990–994(2003).
   Google Scholar
• Markley HG. Topical agents in the treatment of cluster headache. CI.117: Pain Headache Rep. 7(2), 139-143(2003).
   Google Scholar
• Rozen TD. Interventional treatment for cluster headache: a review of the options. CI.117: Pain Headache Rep. 6(1), 57–64 (2002).
   Google Scholar
• Peres MF, Stiles MA, Siow HC eta]. Greater occipatal nerve blockage for cluster headache. Cephalalgia 22 (7), 520–522 (2002).
   PubMed Web of Science ®Google Scholar
• Leone M, Franzini A, D'Amirco D eta]. Stereotactic electrode implant in inferior posterior hypothalamic gray matter to relieve intractable chronic cluster headache: the first reported case. Neurology56\(Suppl. 3), A218 (2001).
   Google Scholar
• Jarrar RG, Black DF, Dodick DW eta]. Outcome of trigeminal nerve section in the treatment of chronic cluster headache. Neurology60(8), 1360–1362 (2003).
   PubMed Web of Science ®Google Scholar
• Bahra A, May A, Goadsby PJ. Cluster headache: a prospective clinical study with diagnostic implications. Neurology 58, 354–361 (2002).
   PubMed Web of Science ®Google Scholar
• International Headache Society Committee on Clinical Trials. Guidelines for trials of drug treatments in tension-type headache. Cephalalgia 15,165–179 (1995).
   PubMed Web of Science ®Google Scholar
• Ashina M, Bendsten L, Jensen R eta! Effect of inhibition of nitric oxide synthase on chronic tension-type headache: a randomised cross-over trial. Lancet 353, 287–289 (1999).
   PubMed Web of Science ®Google Scholar
• Mucke H. Therapies in development for the treatment of migraine. Expert Opin. Investig. Drugs 11 (12), 1813–1820 (2002).
   Google Scholar
• •Current overview of the potential therapeutic targets under active investigation for migraine abortive therapy.
   Google Scholar
• May A, Goadsby PJ. Pharmacological opportunities and pitfalls in the therapy of migraine. CI.117: Opin. Neural 14,341–346 (2001).
   Google Scholar
• Gomez-Mancilla B, Cutler M et al Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia 21,727–732 (2001).
   PubMed Web of Science ®Google Scholar
• McCall RB, Huff R, Chio CL eta! Preclinical studies characterizing the antimigraine and cardiovascular effects of the selective 5-HTE) receptor agonist PNU-142633. Cephalalgia 22 (10), 799–806.
   Google Scholar
• Goadsby PJ. Novel targets for migraine therapy. Cephalalgia 21,267 (2001).
   Google Scholar
• May A, Goadsby PJ. Substance P receptor antagonists in the therapy of migraine. Expert Opin. Investig. Drugs10 (4), 673–678 (2001).
   Google Scholar
• Thomsen LL, Olesen J. Nitric oxide in primary headaches. Gun: Opin. Neural. 14, 315–321 (2001).
   Google Scholar
• Lanssen LH, Ashina M, Christiansen I eta! Nitric oxide synthase inhibition in migraine. Lancet349, 401–402 (1997).
   PubMed Web of Science ®Google Scholar
• Akerman S, Williamson DJ, Kaube H eta! Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. BE Pharmacol 137(1), 62–68 (2002).
   Google Scholar
• Reuter U, Chiarugi A, Bolay H eta! Nuclear factor-KB as a molecular target for migraine therapy. Ann. Neural 51(4), 507–516 (2002).
   PubMed Web of Science ®Google Scholar